Tesidolumab is under clinical development by Novartis and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase II drugs for Paroxysmal Nocturnal Hemoglobinuria have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tesidolumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tesidolumab (LFG-316) is under development for the treatment of paroxysmal nocturnal hemoglobinuria, multi-focal choroiditis, non-infectious intermediate, posterior and panuveitis (MCP). The drug candidate is administered through intravitreal or intravenous routes. It is a fully human HuCAL-based antibody developed based on HuCAL technology. It acts by targeting complement pathway. It was also under development for wet (neovascular /exudative) macular degeneration, geographic atrophy (advanced form of dry age-related macular degeneration) and end stage renal disease and transplant related microangiopathy.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Tesidolumab’s drug-specific PTSR and LoA scores, buy the report here.